Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1171 - PD-L1 status in refractory lymphomas


08 Oct 2016


Poster Display


Semir Vranic


Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375


S. Vranic1, J. Jin2, J. Kimbrough3, N. Ghosh4, N. Bilalovic1, D. Arguello3, Y. Veloso3, T. Hendershot2, A. Dizdarevic5, S. Reddy3, Z. Gatalica3

Author affiliations

  • 1 Pathology, Clinical Centre of Sarajevo University, 71000 - Sarajevo/BA
  • 2 Pathology, Agilent Technologies Inc.,, Santa Clara/US
  • 3 Pathology, Caris Life Sciences, 85224 - Phoenix/US
  • 4 Department Of Hematologic Oncology And Blood Disorders, Levine Cancer Institute, Charlotte/US
  • 5 Hematology, Clinical Centre of Sarajevo University, Sarajevo/BA


Abstract 1171


Targeted immune therapy based on PD-1/PD-L1 suppression has revolutionized the treatment of various solid tumors. A remarkable improvement has also observed in the treatment of patients with refractory/relapsing classical Hodgkin lymphoma (cHL). We investigated PD-L1 status in a variety of treatment resistant lymphomas.


FFPE samples from 79 patients with refractory/resistant lymphomas of B- and T-cell lineages were explored for the expression of PD-L1 (clones: SP142 and SP263, Ventana) using immunohistochemistry. Twelve PD-L1+ cases by IHC were further tested for PD-L1/JAK2/PD-L2 co-amplification using FISH/CISH assays or analyzed for gene copy number variations (CNV) using massively parallel sequencing (Illumina, NGS).


PD-L1 positivity (≥5% positive cancer cells) was present in 32/78 (41%) and 33/72 cases (46%) using SP142 and SP263 antibodies, respectively. Concordance between the two clones was high with only three (4%) discrepant cases (Spearman's correlation coefficient 0.965). The strongest (3 + / ≥ 50% cells) and consistent (10/11 cases) expression was observed in Reed-Sternberg cells of cHL and primary mediastinal B-cell (3/3) lymphoma. Diffuse large B-cell lymphomas (DLBCL) were frequently positive (13/26) irrespective of subtype. Follicular (1/8), peripheral T-cell (2/9) and mantle cell (1/8) lymphomas were rarely positive, while small lymphocytic lymphoma/CLL and marginal zone lymphomas were consistently negative. Co-amplification/CNVs of PD-L1/JAK2/PD-L2 were observed in 3 cases of DLBCL and cHL, respectively.


Over-expression of PD-L1 with an excellent concordance between SP142 and SP263 antibodies was observed in cHL, DLBCL, primary mediastinal B-cell, follicular and peripheral T-cell lymphomas. Clinical relevance and therapeutic implications of co-amplification of PD-L1/JAK2/PD-L2 (50% of tested IHC+ cases) should be further investigated, as other mechanisms are also underlying the overexpression of PD-L1 in lymphomas.

Clinical trial identification

Legal entity responsible for the study



Caris Life Sciences


J. Kimbrough: Employee of Caris Life Sciences, Phoenix, Arizona, USA D. Arguello, Y. Veloso, S. Reddy, Z. Gatalica: Employee of Caris Life Sciences, Phoenix, AZ, USA All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings